DOCSLIB.ORG

Thrombin in Inflammation and Healing: Relevance to Rheumatoid Arthritis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thrombin in Inflammation and Healing: Relevance to Rheumatoid Arthritis 72 Annals of the Rheumatic Diseases 1994; 53: 72-79 REVIEW Ann Rheum Dis: first published as 10.1136/ard.53.1.72 on 1 January 1994. Downloaded from Thrombin in inflammation and healing: relevance to rheumatoid arthritis Ruth Morris, Paul G Winyard, David R Blake, Christopher J Morris Thrombin is classically recognised as factor IIa lymphocytes, neutrophils, and monocytes. 1 of the coagulation cascade, where it catalyses This 'prothrombinase' complex then catalyses the conversion of fibrinogen into fibrin and so cleavage ofprothrombin, with the resulting loss aids in the formation of a blood clot. Active of a 32 kD fragment and formation of active thrombin is generated from prothrombin at the thrombin. cell surface of platelets, lymphocytes, mono- As with other stages in the coagulation cytes, neutrophils and endothelial cells.' It cascade, thrombin generation is controlled by belongs to the serine protease enzyme group, several feedback loops which exert both members of which share a common catalytic positive and negative influences on the amount mechanism and also the triad of amino acids of thrombin formed. For example thrombin at their active site (aspartate-serine-histidine) binds to thrombomodulin, a glycoprotein from which their name derives. Thrombin has found in the endothelial cell membrane and the several forms, the largest and most active of membranes of other cell types including which is 39 kD ct-thrombin. It is able to synovial macrophages.5 6 This binding alters catalyse the cleavage of a wide range ofproteins the thrombin molecule so that it no longer including itself. catalyses fibrinogen cleavage, but instead Recently it has been found that thrombin becomes an efficient activator of protein C, a causes a number of pro-inflammatory and serine protease which inactivates Factor Va.7 In mitogenic effects, many of which appear to this way thrombin is able to curtail its own take place after thrombin cleavage of a generation (fig 1). Raised levels ofthrombomo- G-protein coupled transmembrane receptor. dulin have recently been reported in RA These in vitro observations suggest that synovial fluid,8 suggesting that thrombomo- thrombin may be important in the healing dulin may be important in the control of process, acting as a mediator of inflammation thrombin during inflammatory joint disease. and initiating repair through the stimulation of cell growth. It has also been linked with the http://ard.bmj.com/ development of vascular disease, notably ENDOGENOUS THROMBIN INHIBITORS atherosclerosis.2 However, the multiple actions Uncontrolled thrombin action is prevented by of thrombin implicate this enzyme in the members of the serine protease inhibitor pathogenesis of any disorder where there is (serpin) superfamily,9 which embraces a large sustained vascular injury and cellular number of regulatory plasma proteins such as infiltration. plasminogen activator inhibitor-I (PAI-1) and In particular thrombin may be important ot2-antiplasmin. Serpins display sequence on September 25, 2021 by guest. Protected copyright. during the progression of rheumatoid arthritis homology and share common structural (RA), a chronic inflammatory disease marked features, forming stable 1:1 complexes with by increased vascular permeability, synovial serine protease enzymes. They possess a proliferation, and an abnormal angiogenic reactive centre as part of an external response. Extravascular coagulation is also polypeptide loop, and within this reactive seen in RA, with fibrin deposition being a well centre is a bond that can be cleaved by the documented feature of inflamed synovial target enzyme. Particular serpins tend to be tissue. Advances in immunohistochemical more efficient as inhibitors of certain serine techniques have made it possible to demon- proteases, but none are entirely specific. Inflammation strate the existence of intact coagulation Antithrombin III (AT-III) is the main Research Group, pathways within the rheumatoid synovium.34 circulating inhibitor of thrombin, although London Hospital This review describes current knowledge about other serpins may also contribute. It complexes Medical Coliege, how thrombin works to London, United promote successful with thrombin through its reactive arginine- Kingdom healing, and outlines the pathological serine bond,'01' and can also inhibit Factors R Morris relevance of prolonged and inappropriate IXa, Xa, XIa and XIIa. However, thrombin P G Winyard thrombin in RA. D R Blake activity appears able to bind to the subendothelial C J Morris extracellular matrix without loss of function Correspondence to: and, once bound, is protected from inhibition Ms R Morris, Generation and regulation ofthrombin by plasma AT-III.12 It is therefore not Inflammation Research Group, Arthritis and THE PROTHROMBINASE COMPLEX surprising to find a second serpin, protease Rheumatism Council Thrombin is generated through the action of nexin-1 (PN-1), that directly controls Building, 25-29 Ashfield Street, London El 2AD, Factor Xa and Factor Va, which form a thrombin action at the cell surface. PN-1 is United Kingdom. complex together with phospholipids in the secreted by many cell types in vitro including Accepted for publication membranes of platelets, endothelial cells, human and mouse fibroblasts'3 '4 and bovine 15 September 1993 Thrombin in inflammation and healing. relevance to rheumatoid arthritis 73 complex Ann Rheum Dis: first published as 10.1136/ard.53.1.72 on 1 January 1994. Downloaded from PrtImb V Va v !i o- !2_ Protein C -. I. Thrombomodulin Prothrombin h-romI jIThrombin 1.lj Plasma Antithrombin III Heparin cofactor 11 Other inhibitors Cell surface http://ard.bmj.com/ Protease nexin-1 sr Receptor cleavage on September 25, 2021 by guest. Protected copyright. N C' Thrombin receptor Figure 1 Simplified diagram showing generation, action, and inhibition of thrombin. Solid arrows = activation mechanisms, dotted arrows = inhibitory mechanisms. aortic endothelial cells,'5 where it acts primarily presence of glycosaminoglycans such as as a thrombin inhibitor after cell surface heparin and heparan sulphate,'9 22 which are binding.'6 Thrombin inhibition by a further found in mast cells and on endothelial cell plasma serpin, heparin cofactor II (HC-II), has surfaces respectively. In addition, PAI-I also been demonstrated.'7 HC-II differs from AT- becomes an efficient thrombin inhibitor in the III and PN-1 in that its reactive bond contains presence of heparin.23 The involvement of leucine in preference to the usual arginine glycosaminoglycans in coagulation has recently residue.'8 The physiological significance of this been reviewed,24 and heparin itself is used inhibitor is not well understood. clinically as an anticoagulant because of its The rates of thrombin-inhibition by AT-III, ability to accelerate the inhibition of thrombin PN-1 and HC-II are greatly increased in the by antithrombin III. 74 Morrs, Winyard, Morris Inactivation of serpins in inflamed tissues upregulate expression of the adhesive proteins Serpins are susceptible to inactivation during P-selectin and intercellular adhesion molecule- the inflammatory process, owing to the 1 (ICAM-1) on the endothelial cell membrane, exposed location of their reactive centre on the where the enzyme may act both alone and also Ann Rheum Dis: first published as 10.1136/ard.53.1.72 on 1 January 1994. Downloaded from outside of the molecule. Reactive oxygen synergistically with the cytokines IL-1 and species from neutrophils readily oxidise a tumour necrosis factor-ox (TNF-ot;48 49). critical methionine residue, present in the P-selectin itselfhas recently been shown to play reactive centre of several serpins, for example, a major role during monocyte adhesion to the oxl-antitrypsin (ox,-AT;25). Moreover the rheumatoid synovial vasculature.50 presence of inflammatory mediators such as interleukin-1 (IL-1) stimulates the release of various cell-derived protease enzymes.26 MITOGENICITY AND HEALING Neutrophils produce elastase, a serine The importance of platelet derived growth protease, and connective tissue cells secrete factors (PDGF), the fibroblast growth factors metalloproteinases including collagenase and (FGF), and epidermal growth factor in the stromelysins. These enzymes degrade joint proliferation and healing has been recognised tissues. They can also inactivate serpins by for many years. Like these well-known proteolysis within the exposed loop region, and mitogens, thrombin stimulates proliferation in so may disturb the delicate balance between fibroblastic and other cell types, with the thrombin and its inhibitors. response occurring at low concentrations ofthe Such an event has already been enzyme. In vitro thrombin has been shown to demonstrated for neutrophil elastase, whose be mitogenic for fibroblasts, lymphocytes, associated serpin, ot,-AT, can be cleaved by endothelial cells, vascular smooth muscle cells stromelysin.27 28 The proportion of cleaved and monocytes.1-'5 This mitogenesis can be ol-AT in RA synovial fluid is higher than in stimulated by low levels of active thrombin, osteoarthritic synovial fluid or normal serum,29 and we have observed thrombin-stimulated and consequently RA synovial fluid has a proliferation of murine 3T3 fibroblasts in the reduced capacity for elastase inhibition.30 presence of only five NIH units of thrombin Elastase itself will cleave both AT-III and activity/ml culture medium. Fibroblasts are PN-1 in vitro, and after cleavage these serpins able to regulate such thrombin-induced are no longer effective as
Load more

Recommended publications
  • The Potential Role of Recombinant Activated FVII in the Management of Critical Hemato-Oncological Bleeding: a Systematic Review
    Bone Marrow Transplantation (2007) 39, 729–735 & 2007 Nature Publishing Group All rights reserved 0268-3369/07 $30.00 www.nature.com/bmt REVIEW The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review M Franchini1, D Veneri2 and G Lippi3 1Servizio di Immunoematologia e Trasfusione – Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy; 2Dipartimento di Medicina Clinica e Sperimentale, Sezione di Ematologia, Universita` di Verona, Verona, Italy and 3Dipartimento di Scienze Biomediche e Morfologiche, Istituto di Chimica e Microscopia Clinica, Universita` di Verona, Verona, Italy Recombinant activated factor VII (rFVIIa) is an hemo- situations unresponsive to conventional therapy to control static agent that was originally developed for the excessive bleeding and reduce exposure to allogeneic blood. treatment of hemorrhage in patients with hemophilia and These include intracerebral hemorrhage, oral anticoagu- inhibitors.However, in the last few years rFVIIa has been lant-induced hemorrhage, thrombocytopenia, bleeding employed with success in a broad spectrum of congenital associated with hepatic failure, major surgery, trauma and acquired bleeding conditions.In this systematic review and life-threatening obstetrical, and gynecologic hemor- we present the current knowledge on the use of this drug in rhagic complications.5–9 patients suffering from hemato-oncological disorders, In this systematic review we have collected the available which are quite commonly complicated by severe hemor- data from the literature on the use of rFVIIa in hemato- rhage.On the whole, data in the literature suggest a oncological patients with severe bleeding, unresponsive to potential role for rFVIIa in the management of bleeding standard therapy.
    [Show full text]
  • Recent Developments in the Understanding and Management of Paroxysmal Nocturnal Haemoglobinuria
    review Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria Anita Hill, Stephen J. Richards and Peter Hillmen Department of Haematology, Leeds Teaching Hospitals NHS Trust, Great George Street, Leeds, UK Summary only one G6PD variant enzyme was present in the PNH red cells whereas both variants were present in the residual normal red Paroxysmal nocturnal haemoglobinuria (PNH) has been rec- cells, provided conclusive evidence of the clonal nature of PNH ognised as a discrete disease entity since 1882. Approximately a (Oni et al, 1970). It was clear by the 1980s that PNH cells were half of patients will eventually die as a result of having PNH. deficient in a large number of cell surface proteins, but it was Many of the symptoms of PNH, including recurrent abdominal unclear how this related to either the monoclonal nature of PNH pain, dysphagia, severe lethargy and erectile dysfunction, result or the haemolysis. The development of immortalised cell lines from intravascular haemolysis with absorption of nitric oxide with the PNH abnormality (both B- and T-cells lines) facilitated by free haemoglobin from the plasma. These symptoms, as well the rapid elucidation of the defect (Schubert et al, 1990; Hillmen as the occurrence of thrombosis and aplasia, significantly affect et al,1992;Nakakumaet al,1994).Itbecameclearthatavarietyof patients’ quality of life; thrombosis is the leading cause of proteins normally attached to the cell membrane by a glycolipid premature mortality. The syndrome of haemolytic-anaemia- structure, were found to be abnormal, and that this was due to a associated pulmonary hypertension has been further identified disruption in the glycosylphosphatidylinositol (GPI) biosyn- in PNH patients.
    [Show full text]
  • Haematologica 1999;84:Supplement No. 4
    Educational Session 1 Chairman: W.E. Fibbe Haematologica 1999; 84:(EHA-4 educational book):1-3 Biology of normal and neoplastic progenitor cells Emergence of the haematopoietic system in the human embryo and foetus MANUELA TAVIAN,* FERNANDO CORTÉS,* PIERRE CHARBORD,° MARIE-CLAUDE LABASTIE,* BRUNO PÉAULT* *Institut d’Embryologie Cellulaire et Moléculaire, CNRS UPR 9064, Nogent-sur-Marne; °Laboratoire d’Étude de l’Hé- matopoïèse, Etablissement de Transfusion Sanguine de Franche-Comté, Besançon, France he first haematopoietic cells are observed in es. In this setting, the recent identification in animal the third week of human development in the but also in human embryos of unique intraembryonic Textraembryonic yolk sac. Recent observations sites of haematopoietic stem cell emergence and pro- have indicated that intraembryonic haematopoiesis liferation could be of particular interest. occurs first at one month when numerous clustered We shall briefly review here the successive steps of CD34+ Lin– haematopoietic cells have been identi- human haematopoietic development, emphasising fied in the ventral aspect of the aorta and vitelline the recent progresses made in our understanding of artery. These emerging progenitors express tran- the origin and identity of human embryonic and fetal scription factors and growth factor receptors known stem cells. to be acting at the earliest stages of haematopoiesis, and display high proliferative potential in culture. Primary haematopoiesis in the human Converging results obtained in animal embryos sug- embryo and foetus gest that haematopoietic stem cells derived from the As is the case in other mammals, human haema- para-aortic mesoderm – in which presumptive endo- topoiesis starts outside the embryo, in the yolk sac, thelium and blood-forming activity could be detect- then proceeds transiently in the liver before getting ed as early as 3 weeks in the human embryo by dif- stabilised until adult life in the bone marrow.
    [Show full text]
  • Understanding Megakaryopoiesis and Thrombopoiesis Using Human Stem Cells Models
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models Xiu Li Sim University of Pennsylvania, simxiuli@gmail.com Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Developmental Biology Commons Recommended Citation Sim, Xiu Li, "Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models" (2017). Publicly Accessible Penn Dissertations. 2586. https://repository.upenn.edu/edissertations/2586 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2586 For more information, please contact repository@pobox.upenn.edu. Understanding Megakaryopoiesis And Thrombopoiesis Using Human Stem Cells Models Abstract Human stem cell models (CD34+ hematopoietic progenitors, embryonic stem cells and induced pluripotent stem cells (iPSCs)) are powerful tools for the study of megakaryopoiesis and thrombopoiesis, particularly in situations where mouse models are unavailable or do not accurately recapitulate human physiology or development. In the first part of this thesis, we identified and characterized novel megakaryocyte (MK) maturation stages in MK cultures derived from human stem cells. An immature, low granular (LG) MK pool (defined yb side scatter on flow cytometry) gives rise to a mature high granular (HG) pool, which then becomes damaged by apoptosis and GPIbα (CD42b) shedding. We define an undamaged HG/CD42b+ MK subpopulation, which endocytoses fluorescently-labeled coagulation factor V (FV) from the medium into alpha-granules and releases functional FV+CD42b+ platelet-like particles in vitro and when infused into immunodeficient mice. Importantly, these FV+ platelets have the same size distribution as infused human donor platelets and are preferentially incorporated into clots after laser injury.
    [Show full text]
  • Probing Prothrombin Structure by Limited Proteolysis Laura Acquasaliente, Leslie A
    www.nature.com/scientificreports OPEN Probing prothrombin structure by limited proteolysis Laura Acquasaliente, Leslie A. Pelc & Enrico Di Cera Prothrombin, or coagulation factor II, is a multidomain zymogen precursor of thrombin that undergoes Received: 29 November 2018 an allosteric equilibrium between two alternative conformations, open and closed, that react diferently Accepted: 2 April 2019 with the physiological activator prothrombinase. Specifcally, the dominant closed form promotes Published: xx xx xxxx cleavage at R320 and initiates activation along the meizothrombin pathway, whilst the open form promotes cleavage at R271 and initiates activation along the alternative prethrombin-2 pathway. Here we report how key structural features of prothrombin can be monitored by limited proteolysis with chymotrypsin that attacks W468 in the fexible autolysis loop of the protease domain in the open but not the closed form. Perturbation of prothrombin by selective removal of its constituent Gla domain, kringles and linkers reveals their long-range communication and supports a scenario where stabilization of the open form switches the pathway of activation from meizothrombin to prethrombin-2. We also identify R296 in the A chain of the protease domain as a critical link between the allosteric open-closed equilibrium and exposure of the sites of cleavage at R271 and R320. These fndings reveal important new details on the molecular basis of prothrombin function. Te response of the body to vascular injury entails activation of a cascade of proteolytic events where zymo- gens are converted into active proteases1. In the penultimate step of this cascade, the zymogen prothrombin is converted to the active protease thrombin in a reaction catalyzed by the prothrombinase complex composed of the enzyme factor Xa, cofactor Va, Ca2+ and phospholipids.
    [Show full text]
  • Adhesive Receptor Mac-1 Coordinates the Activation of Factor X On
    Proc. Nati. Acad. Sci. USA Vol. 85, pp. 7462-7466, October 1988 Biochemistry Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade (leukocyte integrins/ADP/tissue factor/procoagulant response) DARIO C. ALTIERI, JAMES H. MORRISSEY, AND THOMAS S. EDGINGTON Vascular Biology Group, Department of Immunology, Research Institute of Scripps Clinic, La Jolla, CA 92037 Communicated by Seymour Klebanoff, June 21, 1988 ABSTRACT Monocytes initiate coagulation through reg- ligand specificity for factor X (20) suggests that Mac-1 ulated surface expression of tissue factor and local assembly of exhibits the multifunctional receptor versatility typical of a proteolytic enzymatic complex formed by tissue factor and other, partially related, integrin receptors (21, 22). factor VIl/activated factor VII. We now show that, in the These observations have now been extended to demon- absence of these initiating molecules, monocytes and cell lines strate that, in the absence of demonstrable TF or TF: of monocytic/myeloid differentiation can alternatively initiate VII/VIa complex, ADP-stimulated monocytes and myeloid coagulation after exposure to ADP. The molecular basis for this cells bearing Mac-1 directly convert surface-bound factor X procoagulant response consists oftwo distinct events. First, cell to a proteolytically active derivative characteristic of factor stimulation with ADP induces high-affinity binding of coagu- Xa. This appears to represent an additional mechanism of lation factor X to the surface-adhesive receptor Mac-1. Locally, initiating the coagulation protease cascade on the surface of Mac-i-concentrated factor X is then rapidly proteolytically cells.
    [Show full text]
  • Immunological Responses to Total Hip Arthroplasty
    Journal of Functional Biomaterials Review Immunological Responses to Total Hip Arthroplasty Kenny Man 1, Lin-Hua Jiang 2 ID , Richard Foster 3 and Xuebin B Yang 1,4,* 1 Biomaterials and Tissue Engineering Group, School of Dentistry, University of Leeds, Leeds LS2 9JT, UK; mnkklm@leeds.ac.uk 2 School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds LS2 9JT, UK; l.h.jiang@leeds.ac.uk 3 School of Chemistry, University of Leeds, Leeds LS2 9JT, UK; r.foster@leeds.ac.uk 4 Medical College and the First Affiliated Hospital, Henan University of Science and Technology, Henan 471023, China * Correspondence: x.b.yang@leeds.ac.uk; Tel.: +44-113-3436162 Academic Editor: Wilson Wang Received: 6 April 2017; Accepted: 25 July 2017; Published: 1 August 2017 Abstract: The use of total hip arthroplasties (THA) has been continuously rising to meet the demands of the increasingly ageing population. To date, this procedure has been highly successful in relieving pain and restoring the functionality of patients’ joints, and has significantly improved their quality of life. However, these implants are expected to eventually fail after 15–25 years in situ due to slow progressive inflammatory responses at the bone-implant interface. Such inflammatory responses are primarily mediated by immune cells such as macrophages, triggered by implant wear particles. As a result, aseptic loosening is the main cause for revision surgery over the mid and long-term and is responsible for more than 70% of hip revisions. In some patients with a metal-on-metal (MoM) implant, metallic implant wear particles can give rise to metal sensitivity.
    [Show full text]
  • MONOCYTES CAN BE INDUCED by LIPOPOLYSACCHARIDE-TRIGGERED T LYMPHOCYTES to EXPRESS FUNCTIONAL FACTOR VII/Viia PROTEASE ACTIVITY B
    MONOCYTES CAN BE INDUCED BY LIPOPOLYSACCHARIDE-TRIGGERED T LYMPHOCYTES TO EXPRESS FUNCTIONAL FACTOR VII/VIIa PROTEASE ACTIVITY BY BETTY P. TSAO, DARYL S. FAIR, LINDA K. CURTISS, AND THOMAS S. EDGINGTON Downloaded from http://rupress.org/jem/article-pdf/159/4/1042/1094234/1042.pdf by guest on 27 September 2021 From the Department of hnmunology, The Research Institute of Scripps Clinic, La Jolla, California 92037 The monocyte has been perceived as a relatively inactive member of the monocyte/macrophage series, i.e., a cell in transport to an anatomic site where differentiation to the macrophage will occur. Modification of this perception is merited in light of the ready capacity of monocytes, as well as their tissue- localized progeny, the elicited macrophage, to initiate and propagate coagulation protease pathways (reviewed in references 1-4). The human monocyte given appropriate direct collaboration by bacterial lipopolysaccharide (LPS), 1 immune complex-stimulated T lymphocytes (5-7), or a lymphokine (8, 9) from allogene- icaily or antigen-stimulated T cells (10, 1 1), produces and expresses on its surface a cell membrane lipoprotein, i.e., tissue factor, the initiating cofactor of the extrinsic coagulation protease pathway (12, 13). This initiating event is attribut- able to the calcium-dependent binding of Factor VII or VIIa to tissue factor (14, 15) to form a molecular complex capable of efficiently converting the zymogen Factor X to its active form by virtue of the limited proteolytic specificity of Factor VII and VIIa. This protease, the only coagulation protease that is proven to be active in the zymogen form (16), also can proteolytically activate Factor IX, of the intrinsic pathway (17).
    [Show full text]
  • BIO 2402 Resource #2
    BIO 2402 Human Anatomy & Physiology Hi everyone! I hope you all are feeling confident in your studies of the endocrine system and are ready to tackle the last chapter that will be on your first lecture exam! We will be covering the first chapter of cardiovascular system that focuses on the blood. I will include practice questions for both the endocrine system (as a review) as well as the cardiovascular system. Please let me know if you have any questions! Remember that the Tutoring Center offers free individual and group tutoring for this class. Our Group Tutoring sessions will be every Wednesday from 6:00-7:00 PM CST. You can reserve a spot at https://baylor.edu/tutoring. KEY WORDS: Intrinsic & Extrinsic Pathway, Cell Differentiation, Plasma Proteins, Relative Abundance - Composition of Blood: Plasma and Formed Elements Whole Blood = Plasma + Formed Elements Hematocrit = Formed Elements Plasma = 93% water, 7% Plasma Proteins 1. Albumin: smallest most abundant 2. Globulin: second most abundant 1. Alpha- transports bilirubin 2. Beta- transports metals 3. Gamma- aka immunoglobulins or antibodies, immunization 3. Fibrinogen: secreted from the liver, least abundant - Red Blood Cells: Most abundant formed element in the blood - White Blood Cells: Have two subclasses - Granulocytes or Polymorphonuclear leukocytes: neutrophils, eosinophils, and basophil - Agranulocytes or Mononuclear leukocytes: lymphocytes and monocytes - For each blood cell please ensure that you know the following: function, origin, formation, and destruction. Dr. Taylor likes to ask questions about the different function of the blood cells, so it is imperative that you know the difference between each type. Relative Abundance: within the whole blood each separate element as a specific concentration, or abundance relative to the concentration of the other elements.
    [Show full text]
  • Did Dinosaurs Have Megakaryocytes? New Ideas About Platelets and Their Progenitors
    Did dinosaurs have megakaryocytes? New ideas about platelets and their progenitors Lawrence F. Brass J Clin Invest. 2005;115(12):3329-3331. https://doi.org/10.1172/JCI27111. Review Series Introduction Biological evolution has struggled to produce mechanisms that can limit blood loss following injury. In humans and other mammals, control of blood loss (hemostasis) is achieved through a combination of plasma proteins, most of which are made in the liver, and platelets, anucleate blood cells that are produced in the bone marrow by megakaryocytes. Much has been learned about the underlying mechanisms, but much remains to be determined. The articles in this series review current ideas about the production of megakaryocytes from undifferentiated hematopoietic precursors, the steps by which megakaryocytes produce platelets, and the molecular mechanisms within platelets that make hemostasis possible. The underlying theme that connects the articles is the intense investigation of a complex system that keeps humans from bleeding to death, but at the same time exposes us to increased risk of thrombosis and vascular disease. Find the latest version: https://jci.me/27111/pdf Review series introduction Did dinosaurs have megakaryocytes? New ideas about platelets and their progenitors Lawrence F. Brass Departments of Medicine and Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Biological evolution has struggled to produce mechanisms that can limit blood loss following injury. In humans and other mammals, control of blood loss (hemostasis) is achieved through a combination of plasma proteins, most of which are made in the liver, and platelets, anucleate blood cells that are produced in the bone marrow by megakaryocytes.
    [Show full text]
  • Tumor Cell Generation of Thrombin Via Functional Prothrombinase Assembly1
    [CANCER RESEARCH 45, 5521-5525, November 1985] Tumor Cell Generation of Thrombin via Functional Prothrombinase Assembly1 Livingston VanDeWater, Paula B. Tracy,2 Denise Aronson, Kenneth G. Mann,2 and Harold F. Dvorak3 Departments of Pathology, Beth Israel Hospital and Harvard Medical School and the Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215 (L. V. D. W., D. A., H. F. D.¡,and Hematology Research Section, Mayo Clinic, Rochester, Minnesota 55095 [P. B. T., K. G. M.¡ ABSTRACT These classical pathways are now recognized as a network of activation and feedback reactions that converge on a final com Prothrombinase affects the proteolytic conversion of pro- mon pathway of prothrombinase and thrombin generation. Pro- thrombin to thrombin and is the penultimate enzyme in the coagulants acting at steps proximal to this common pathway will common coagulation pathway. Prothrombinase is a complex in be ineffective in generating thrombin and depositing fibrin if which the proteinase, Factor Xa, a cofactor, Factor Va, and prothrombinase is not active. calcium are bound to a membrane surface to generate the active Prothrombinase complex formation is thus a critical step in enzyme. Guinea pig line 1 and line 10 tumor cells, grown as coagulation and one that has been largely neglected in studies primary cultures from ascites tumors or as cell lines in culture, of tumor-associated clotting. Prothrombinase is a complex of an provide a surface that interacts with coagulation Factor Va and active protease (Factor Xa) with a non-enzymatic cofactor (Fac Xa and with calcium ions to form this enzyme complex.
    [Show full text]
  • Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19
    International Journal of Molecular Sciences Review Pathophysiological Association of Endothelial Dysfunction with Fatal Outcome in COVID-19 Tatsuya Maruhashi 1 and Yukihito Higashi 1,2,* 1 Department of Cardiovascular Regeneration and Medicine, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima 734-8553, Japan; maru0512@hiroshima-u.ac.jp 2 Division of Regeneration and Medicine, Medical Center for Translational and Clinical Research, Hiroshima University Hospital, Hiroshima 734-8551, Japan * Correspondence: yhigashi@hiroshima-u.ac.jp; Tel.: +81-82-257-5831 Abstract: The outbreak of coronavirus disease 2019 (COVID-19) caused by the betacoronavirus SARS-CoV-2 is now a worldwide challenge for healthcare systems. Although the leading cause of mortality in patients with COVID-19 is hypoxic respiratory failure due to viral pneumonia and acute respiratory distress syndrome, accumulating evidence has shown that the risk of thromboembolism is substantially high in patients with severe COVID-19 and that a thromboembolic event is another major complication contributing to the high morbidity and mortality in patients with COVID- 19. Endothelial dysfunction is emerging as one of the main contributors to the pathogenesis of thromboembolic events in COVID-19. Endothelial dysfunction is usually referred to as reduced nitric oxide bioavailability. However, failures of the endothelium to control coagulation, inflammation, or permeability are also instances of endothelial dysfunction. Recent studies have indicated the possibility that SARS-CoV-2 can directly infect endothelial cells via the angiotensin-converting enzyme 2 pathway and that endothelial dysfunction caused by direct virus infection of endothelial Citation: Maruhashi, T.; Higashi, Y. cells may contribute to thrombotic complications and severe disease outcomes in patients with Pathophysiological Association of COVID-19.
    [Show full text]